Effectiveness of vaccinating household contacts in addition to chemoprophylaxis after a case of meningococcal disease: A systematic review

Epidemiology and Infection

Volumn 136, Issue 11, 2008, Pages 1441-1447

  Hoek, M R ^a,b   Christensen, H ^b   Hellenbrand, W ^c   Stefanoff, P ^d   Howitz, M ^e   Stuart, J M ^b  

^a ECDC   (Sweden)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c ROBERT KOCH INSTITUTE   (Germany)

^d NATIONAL MEDICINES INSTITUTE   (Poland)

^e STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; MENINGOCOCCUS VACCINE; RIFAMPICIN;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; EMBASE; EPIDEMIC; FOLLOW UP; HOUSEHOLD; HUMAN; INFORMATION PROCESSING; MEDLINE; MENINGOCOCCOSIS; META ANALYSIS; NEISSERIA MENINGITIDIS; PREVALENCE; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; CHEMOPREVENTION; DISEASE TRANSMISSION, HORIZONTAL; FAMILY CHARACTERISTICS; FAMILY HEALTH; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES;

EID: 54049122254     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268808000770     Document Type: Review

References (28)

1. Ramsay M, Fox A, Chandra M. Invasive Neisseria meningitidis in Europe. European Union Invasive Bacterial Infectious Surveillance Network, 2003-2004 (http://www.euibis.org).
2. Borg J, et al. Outcomes of meningococcal disease during the teenage peak. Archives of Diseases in Childhood 2003; 88: 426-429.
3. Wang VJ, et al. Meningococcal disease among children who Eve in a large metropolitan area, 1981-1996. Clinical Infectious Disease 2001; 32: 1004-1009.
4. De Wals P, et al. Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts. Journal of Infection 1981; 3 53-61.
5. Munford RS, et al. Spread of meningococcal infection within households. Lancet 1974; 1: 1275-1278.
6. Purcell B, et al. Effectiveness of antibiotics in preventing meningococcal disease after a case: Systematic review. British Medical Journal 2004; 328: 1339-1342.
7. Fraser A, et al. Antibiotics for preventing meningococcal infections [Review]. The Cochrane Library, 2005; Chichester, UK; John Wiley & Sons Ltd.
8. Stuart JM, et al. Does eradication of meningococcal carriage in household contacts prevent secondary cases of meningococcal disease? British Medical Journal 1989; 298: 569-570.
9. Hoek M, et al. A European survey on public health policies for managing cases of meningococcal disease and their contacts. Eurosurveillance 2008; 13(10).
10. Begg N. Policies for public health management of meningococcal disease. Journal of Epidemiology and Community Health 1999; 53 16.
11. Cooke RPD, et al. Secondary cases of meningococcal infection among close family and household contacts in England and Wales, 1984-7. British Medical Journal 1989; 298: 555-558.
12. De Wals P, et al. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 2004; 22: 1233-1240.
13. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database of Systematic Reviews 2005, Issue 1, Art. No.: CD001093. doi:10.1002/14651858.CD001093.pub2.
14. Hastings L, et al. A retrospective survey of clusters of meningococcal disease in England and Wales, 1993 to 1995: Estimated risks of further cases in household and educational settings. Communicable Disease Report Review 1997; 7: 195-200.
15. Meningococcal Disease Surveillance Group. Meningococcal disease: secondary attack rate and chemoprophylaxis in the United States, 1974. Journal of the American Medical Association 1976; 235: 261-265.
16. Scholten RJP, et al. Secondary cases of meningococcal disease in the Netherlands, 1989-1990 A reappraisal of chemoprohylaxis. Nederlands Tydschrift van de Geneeskunde 1993; 137: 1505-1508.
17. Samuelsson S, et al. Prevention of secondary cases of meningococcal disease in Denmark. Journal of Epidemiology and Infection 2000; 124: 433-440.
18. Stefanoff P, et al. Detection of meningococcal household clusters and their prophylaxis in changing epidemiological situation of invasive meningococcal disease in Poland. Eurosurveillance 2008; 13(10).
19. CDC. Control and prevention of meningococcal disease and control and prevention of serogroup C meningococcal disease: Evaluation and management of suspected outbreaks. Morbidity and Mortality Weekly Report 1997; 46: 1-21.
20. Lewis EN, et al. Childhood influenza: Number needed to vaccinate to prevent 1 hospitalization or outpatient visit. Pediatrics 2007; 120: 467-472.
21. Kelly H, et al. The number needed to vaccinate (NNV) and population extensions of the NNV: Comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine 2004; 22: 2192-2198.
22. Samuelsson S. Surveillance and prevention of meningococcal disease in Denmark 1980-96 (Ph.D. thesis). Faculty of Health Sciences, Southern Denmark, 1999.
23. Jackson LA, et al. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. American Journal of Public Health 1995; 85: 843-845.
24. Greenwood M, Hassan-King M, Whittle HC. Prevention of secondary cases of meningococcal disease in house-hold contacts by vaccination. British Medical Journal 1978; 21: 1317-1319.
25. Davison KL, et al. Clusters of meningococcal disease in school and preschool settings in England and Wales: What is the risk? Archives of Disease in Childhood 2004; 89: 256-260.
26. Hoebe CPA, et al. Space-time clustering analysis of invasive meningococcal disease. Emerging Infectious Diseases 2004; 10 1621-1626.
27. Trotter C, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364 365-367.
28. Granoff D, Pollard A. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatric Infectious Disease Journal 2007, 26: 716-722.